Mumbai-bound Jet Airways flight aborts take-off at Riyadh Airport, departs runway

The Organisation of Islamic Cooperation (OIC) has said it rejects US President  Donald Trump 's recently unveiled Middle East plan.

The 57-member body, which held a summit on Monday  to discuss the plan in Saudi Arabia's Jeddah, said in a statement that it "calls on all member states not to engage with this plan or to cooperate with the US administration in implementing it in any form".

Requested by the Palestinian leadership, the meeting of the body came two days after the Arab League rejected Trump's so-called "deal of the century", saying: "It does not meet the minimum rights and aspirations of Palestinian people."

Addressing a pro-Israel audience at the White House with Israeli Prime Minister Benjamin Netanyahu by his side, Trump on Tuesday described his long-delayed plan for resolving the Israeli-Palestinian conflict as a "win-win solution" for both sides.

The US president said his proposed deal would ensure the establishment of a two-state solution, promising Palestinians a state of their own with a new capital in Abu Dis, a suburb just outside Jerusalem. Trump also said Jerusalem would be the "undivided capital" of Israel. The Palestinians want both occupied East Jerusalem and the West Bank to be part of a future state.

Palestinian leaders, who were absent during the announcement and had rejected the proposal even before its release, denounced the plan as "a new Balfour Declaration" that heavily favoured Israel and would deny them a viable independent state.

The OIC said in a statement on Twitter on Sunday that its "open-ended executive committee meeting" at the level of foreign ministers would "discuss the organisation's position after the US administration announced its peace plan".

With member states from four continents, the OIC is the second-largest intergovernmental organisation in the world after the United Nations, with a collective population reaching more than 1.8 billion.

The majority of its member states are Muslim-majority countries, while others have significant Muslim populations, including several African and South American countries. While the 22 members of the Arab League are also part of the OIC, the organisation has several significant non-Arab member states, including Turkey, Iran and Pakistan. It also has five observer members, including Russia and Thailand.

Iran 'barred'

Meanwhile, Iran on Monday accused its regional rival Saudi Arabia of blocking its officials from attending the OIC meeting.

"The government of Saudi Arabia has prevented the participation of the Iranian delegation in the meeting to examine the 'deal of the century' plan at the headquarters of the Organization of Islamic Cooperation," Fars news agency quoted Abbas Mousavi, spokesman for Iran's foreign ministry, as saying.

Mousavi said Iran - one of the countries to strongly condemn Trump's plan - had filed a complaint with the OIC and accused its regional rival of misusing its position as the host for the organisation's headquarters.

There was no immediate comment from Saudi officials.

Following the unveiling of Trump's plan, the Saudi foreign ministry expressed appreciation for Trump's efforts and support for direct peace negotiations under Washington's auspices, while state media reported that King Salman had called Palestinian President Mahmoud Abbas to reassure him of Riyadh's unwavering commitment to the Palestinian cause.

The announcement of Trump's plan drew mixed responses from Arab states.

Observers said the reaction was indicative of the division among Arab countries and their inability to prioritise the Palestinian people's plight over domestic economic agendas and political calculations in relation to the Trump administration.

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

New Delhi, Feb 13: Tibetan spiritual leader the Dalai Lama has congratulated AAP supremo Arvind Kejriwal for his party's stupendous victory in the Delhi Assembly polls, saying the people of the national capital will continue to benefit from his leadership.

Responding to the Dalai Lama's statement, Kejriwal in a tweet on Wednesday said, "Am humbled by the kind words and blessings from His Holiness The Dalai Lama. Thank you very much @DalaiLama."

Referring to the Happiness Curriculum for government schools in Delhi, the Dalai Lama said he has a deep admiration for the efforts the AAP government has made towards "shaping better, happier human beings with improved values".

"These measures will have a positive impact on children's overall education, as well as helping the poor to fulfil their dreams of improving their lives," he said.

He also lauded the AAP government's initiative to incorporate aspects of inner mental development into the school curriculum.

"Through such initiatives, you are showing a path to the rest of India," the Dalai Lama added.

In a near-repeat performance of 2015, the Aam Aadmi Party on Tuesday retained power with a stunning victory, winning 62 of the 70 assembly seats and leaving the BJP with just eight seats.